<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To explore feasibility and efficacy of unrelated HLA matched donor marrow transplantation in treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, one case (male, 31 years old) of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>-refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>) has been received unrelated HLA-matched donor transplantation </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="28901">Busulfan</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, Ara-C, MeCCNU and antithymocyte globulin (ATG) were used for preparative regimen </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="168396">Mycophenolate</z:chebi> mofetile, <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> and short-term <z:chebi fb="0" ids="44185">methotrexate</z:chebi> were used for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> prophylaxis </plain></SENT>
<SENT sid="3" pm="."><plain>The results showed that neutrophil of &gt; 0.5 x 10(9)/L, platelet of 58 x 10(9)/L and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> of 114 g/L were observed at 10, 20 days and 3 months respectively post transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>Disease-free survival without GVHD was 9 months </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, unrelated HLA matched donor marrow transplantation is an effective approach for treatment of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>